Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
206502
Biotechnology
Next Earning date - 07 May 2025
206502
Biotechnology
Next Earning date - 07 May 2025
Relative Strenght
9Volume Buzz
48149%Earning Acce
NoDist 52w H.
99%